Abstract: Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.

Abstract: The present invention relates to methods of determining the levels of 3-methylhistidine before and after a meal in a companion animal, wherein the meal is a pet foodstuff having a particular protein to fat ratio, which is useful in decreasing the levels of 3-methydlhistidine post-prandially and having the beneficial effects as described herein. The pet foodstuff comprises a ratio of protein to fat of 1:0.27 to 1:0.63 on a gram:gram as fed or dry matter basis. The pet foodstuff described is fed to a companion animal for use in reducing and/or preventing sarcopenia. The present invention also relates to methods of feeding the pet foodstuff described and/or dietary regimes to provide the companion animal with the benefit of reducing and/or preventing sarcopenia.

Abstract: Provided are methods of producing product nucleic acids involving the use of oligonucleotides that are modified by the application of a stimulus. Aspects of such methods may include producing product nucleic acids using de-activatable oligonucleotides that are deactivated by a de-activating stimulus, as well as methods that may include producing product nucleic acids using activatable oligonucleotides that are activated by an activating stimulus and de-activatable oligonucleotides that are deactivated by a de-activating stimulus. Also provided are kits, compositions and devices that include de-activatable oligonucleotides or activatable and de-activatable oligonucleotides, e.g., for use in performing the methods as described herein.

Abstract: Disclosed herein include systems, methods, compositions, and kits for immune repertoire profiling. There are provided, in some embodiments, primer panels enabling the determination of the nucleotide sequence of the complete variable region of nucleic acids encoding mouse B cell receptor (BCR) and T cell receptor (TCR) polypeptides. In some embodiments, the method comprises single cell transcriptomic analysis.

Abstract: A single nucleotide polymorphism (SNP) that results in development of a Type VI collagen, alpha 1 chain-related disorder, and the use of the SNP to identify individuals at risk for developing COL6-related disorders (COL6-RD). Also provided are antisense oligomers for treating individuals at risk for developing COL6-RD, as well as methods for screening compounds for their potential as therapeutic agents.

Abstract: The present invention relates to a set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival or of predicting the likelihood of a recurrence and/or aggressiveness of a breast cancer in a breast cancer patient. The present invention also relates to a method for predicting the likelihood of a breast cancer patient's survival or the likelihood of the recurrence or aggressiveness of a breast cancer in a breast cancer patient, as well as to a kit for use in such method.

Abstract: The present invention relates to a method, in particular an in vitro method, for identifying B cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for Low density lipoprotein receptor-related protein 5 (LRP5), wherein a demethylation or lack of methylation of said gene region is indicative for a B cell, when compared to a non-B cell. The analyses according to the invention can identify B cells on an epi-genetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying B cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Further claimed are kits and specific primers and probes for identifying methylation.

Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

Abstract: Provided herein are oligonucleotide probes for detecting 2019 novel coronavirus (2019-nCoV). The probes are modified at their 5? ends with a fluorophore (e.g., fluorescein), and are also modified (e.g., at their 3? ends) with a moiety capable of quenching fluorescence from the fluorophore. The moiety is based on the IQ-4 or IQ-2 quencher. Also provided are kits including one or more of such oligonucleotide probes, and methods of detecting 2019-nCoV and/or diagnosing COVID-19 using the oligonucleotide probes and kits described herein.

Abstract: An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.

Abstract: The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.

Abstract: Presented herein are methods and compositions for enhancing specific enrichment of target sequences in a nucleic acid library. Off-target hybridization probes may be used to reduce binding and/or capture of off-target regions of a nucleic acid library in a targeted sequencing workflow. The off-target hybridization probes may be specific for locations known to generate off-target sequencing reads for a particular set of hybridization probes.

Abstract: The invention relates to a carotenoid for use in the treatment or prevention of stress induced conditions, and in particular it relates to the treatment or prevention of a disease mediated by glucocorticoid receptor activity. The invention also relates to a cosmetic method for preventing premature-aging of skin in a subject which comprises administering a carotenoid to said subject. Finally, the invention relates to a method for modulating the activity of a glucocorticoid receptor comprising contacting the receptor with a carotenoid.

Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.

Abstract: Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present application provides compositions and methods for determining a disease or condition in a subject. The method comprises contacting a body fluid with a molecule comprising a reporter thereof and the reported is cleaved by an agent in the body fluid. Diseases and conditions that can be determined by the method are also described.

Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.

Abstract: The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

Abstract: The present invention provides various compositions and methods useful for the treatment of BRAF-mutant tumors, such as BRAFV600E-mutant tumors. In some embodiments such methods involve administration of three active agents—a RAF inhibitor, a MEK inhibitor, and an ERK inhibitor. The present invention also provides novel intermittent dosing regimens for these three active agents that maintain maximal anti-tumor efficacy while also minimizing toxicity.

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

Abstract: A method of forming a polymer matrix array includes treating a surface within a well of a well array with a surface compound including a surface reactive functional group and a radical-forming distal group; applying an aqueous solution including polymer precursors to the well of the well array; and activating the radical-forming distal group of the surface coupling compound with an initiator and atom transfer radical polymerization (ATRP) catalyst to initiate radical polymerization of the polymer precursors within the well of the well array to form the polymer matrix array.

Abstract: There is a need for more effective and efficient predictive data analysis solutions for processing genetic sequencing data. This need can be addressed by, for example, techniques for performing predictive data analysis based on genetic sequences that utilize at least one of cross-variant polygenic risk modeling using genetic risk profiles, cross-variant polygenic risk modeling using functional genetic risk profiles, per-condition polygenic clustering operations, cross-condition polygenic predictive inferences, and cross-condition polygenic diagnoses.

Abstract: A system and method for contaminant control, often infection control, with multiple time and space domains that integrate active and passive infection control devices and processes that preferably feature infection control active additives with controllable dis-passivation to limit post-consumption environmental impact. Additionally, the system executes the infection control devices and process transactions by controlling the dispatch of infection control tasks centered around a potential infection control incidence and/or cross-contamination locations from assets or personnel having probabilistic infection rates to increase compliance of infection control preventative measures.

Abstract: The present invention relates to series of peptidomimetic compounds selectively targeting CBX8 of polycomb chromobox protein homolog proteins. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases involved CBX8 pharmacology, including various cancers and leukemia, by administering therapeutically effective amounts of such compound alone or together with other therapeutics, are within the scope of this disclosure.

Abstract: A system for customizing treatments. The system includes a computing device configured to record a user biological extraction containing an element of user physiological data. The computing device is configured to receive condition state training data and generate a condition state model utilizing a first machine-learning algorithm. The computing device is configured to calculate a condition state label using the condition state model. The computing device is configured to select a treatment model utilizing the condition state label. The computing device is configured to generate a treatment model and output a plurality of treatments utilizing the treatment model.

Abstract: Embodiments of the present invention provide methods, computer program products, and systems for classification and identification of cancer genes while correcting for sample bias for tumor-derived genomic features as well as other biased features using machine learning techniques. Embodiments of the present invention can be used to receive a set of genes that include a first gene and a subset of synthetic genes that include similar features to the first gene and receive a set of gene labels associated with physiological characteristics. Embodiments of the present invention can estimate probabilities that genes in the set of genes are associated with gene labels in the set of gene labels using a machine learning classifier and estimate an effective probability range for the first gene and each gene label based, at least in part, on the first gene's estimated probabilities and the estimated probabilities of one or more of the synthetic genes.

Abstract: Novel Coronavirus/MERS-CoV/Influenza Virus A/B Multiple Rapid Detection Kit is disclosed. The kit has the advantages of high sensitivity, good specificity, high speed (3-15 minutes), simplicity and low cost.

Abstract: The present invention concerns a method of sequencing immobilized polynucleotides in which beads which are tethered to the solid support are used as labels to identify bases within the polynucleotides. The beads carry sets of probes or bases which can bind to the polynucleotide allowing identification of the target base(s). Identification of the base(s) is achieved through sequential application of different cleavage means specific to different probes/bases carried on the beads. Also provided is an apparatus for performing the method and a kit comprising the apparatus and other components necessary for performing the method.

Abstract: The present disclosure relates to vectors for cloning and expressing genetic material including but not limiting to antibody gene or parts thereof and methods of generating said vectors. Said vectors express the antibody genes in different formats such as Fab or scFv as a part of intertransfer system, intratransfer system or direct cloning and expression in individual display systems. In particular, phage display technology is used to clone and screen potential antibody genes in phagemid which is followed by the transfer of said genes to yeast vector for further screening and identification of lead molecules against antigens. The present vectors have numerous advantages including uniquely designed inserts/expression cassettes resulting in efficient and smooth transfer of clonal population from phage to yeast vectors resulting in efficient library preparation and identification of lead molecules.

Abstract: Systems, methods, and devices for analyzing small volumes of fluidic samples, as a non-limiting example, less than twenty microliters are provided. The devices are configured to make a first sample reading, for example, measure an energy property of the fluid sample, for example, osmolality, make a second sample reading, for example, detecting the presence or concentration of one or more analytes in the fluid sample, or make both the first sample reading and the second sample reading, for example, measuring the energy property of the fluid sample as well as detecting the presence or concentration of one or more analytes in the fluid sample.

Abstract: A system and method for alerting a healthcare provider to ineffective prescribed medications is provided. A laboratory system receives test results with genetic markers for a patient, queries a database containing medications known to be ineffective in persons having particular genetic markers to determine whether any medications prescribed by, or likely to be prescribed by, a healthcare provider to the patient are known to be ineffective in persons having the same genetic markers as the patient, and transmits an alert containing such information to a healthcare provider system for the healthcare provider.

Abstract: Embodiments disclosed here are production methods and compositions of engineered immune cells, such as B or T lymphocytes, from limited lineage myeloid progenitor cells, or from pluripotent stem cells, or from multilineage hematopoietic progenitor cells comprising the addition of various cell differentiation transcription factors and inhibiting epigenetic histone methylations in said cells.

Abstract: The present invention discloses a recombinant vector constructed from an encoding gene of a nitrilase mutant, a recombinant genetic engineered strain and application thereof the nucleotide sequence of the gene is shown in SEQ ID No. 5, and the amino acid sequence of the mutant is shown in SEQ ID No. 6. In the present invention, by the protein molecular modification, thermostability of the purified nitrilase LNIT5 is increased by up to 4.5 folds; and by utilizing recombinant E. coli containing the nitrilase mutant to hydrolyze 1-cyanocyclohexylacetonitrile at a high temperature (45° C.), product tolerance is increased, activity of NITS-L201F is increased by 20%, and the mutant NITLNIT5-AcN can completely hydrolyze 750 mM 1-cyanocyclohexylacetonitrile within 8 hours and achieve an doubled conversion rate.

Abstract: The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

Abstract: Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.

Abstract: The present invention provides a method for detecting Brucella infection, i.e., a serum and blood cell synchronous detection method. The detection method comprises two operation steps of serum sample detection and living blood cell sample detection and uses a supporting kit. The kit can be used for pretreatment of blood samples for clinically detecting Brucella in vitro. The serum and blood cell synchronous detection method can be used for early clinical rapid diagnosis of Brucella infection and medication guidance in the treatment process, and can also be used for prognosis, epidemiological survey of brucellosis, etc. The present invention can also be used for early clinical rapid diagnosis of other intracellular parasitic infection.

Abstract: The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like.

Abstract: The present invention provides a method of measuring the quality of therapeutic cells through real-time glutathione monitoring.

Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.

Abstract: The present invention relates to methods of nucleic acid analyte detection by PCR. In particular, methods and kits for the detection of a plurality of nucleic acid analytes and the generation of kinetic signatures are provided. Further provided are methods and kits of nested PCR and PCR using limiting primers.

Abstract: Disclosed herein are methods and compositions for determining an improved estimate of the fractional abundance of target analytes (e.g., specific polynucleotide sequences) in a sample using a nanopore sensor having one or more nanopores-, e.g., by correcting errors inherent to identifying and correlating electrical signals to amounts of a target analyte or reference analyte in a sample.

Abstract: Methods of culturing and detecting a biomarker which may be associated with autoimmune diseases, in particular inflammatory bowel disease and Crohn's disease; also a screening method for substances suitable for the treatment of inflammatory bowel disease including Crohn's disease; the method including culturing a biomarker in a culture media which includes a culture broth, OADC, PANTA and Mycobactin J.

Abstract: Systems, methods, and non-transitory computer readable media may be configured to access first database and a second database. The first database may be structured for a first data type, and may include a first data of the first data type. The second database may be structured for a second data type different from the first datatype, and may include a second data of the second data type. The second data may be associated with the first data. A first information request relating to the first data and a second information request relating to the second data may be received. A first response to the first information request may be determined based on the second data. A second response to the second information request may be determined based on the first data. An interface, through which the first response or the second response is accessible, may be provided.

Abstract: Methods and systems for using encapsulated microbubbles to process biological samples are disclosed. According to one aspect, a method for using encapsulated microbubbles to process a biological sample includes creating a mixture comprising encapsulated microbubbles mixed with a biological sample and adding activation energy to the mixture to cause at least some of the microbubbles to oscillate or burst and thereby process the sample, including effecting cell lysis, shearing DNA, and/or performing tissue dispersion.

Abstract: The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

Abstract: Provided are detection means and method specific for the genus Cronobacter (E. sakazakii) which are sensitive by using a target molecule which is multiple existent in Cronobacter cells.

Abstract: The present invention relates to a method for prenatal diagnosis using digital PCR, and more particularly to a method for providing information for diagnosis of chromosomal aneuploidy in a fetus, comprising: (a) extracting DNAs from pregnant woman's blood; (b) classifying the DNAs according to size to obtain DNAs having a size of 1,000 bp or less; (c) performing digital PCR using the obtained DNAs of step (b), for a control gene located on a chromosome not associated with chromosomal aneuploidy and a target gene located on a chromosome associated with chromosomal aneuploidy; (d) calculating a ratio of a quantitative digital PCR value of the target gene to a quantitative digital PCR value of the control gene; and (e) determining that when the ratio calculated in step (d) is 0.70-1.14, a chromosome number of the fetus is normal.

Abstract: Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESRI) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.

Abstract: The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.